Avicanna Inc., a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products announces that, with immediate effect, Setu Purohit will no longer serve as President and Chief Legal Officer of the Company. He will remain a member of the Company’s board of directors.
The Company continues to execute on its transitional plans as it evolves from a pre-revenue R&D stage company into a rapidly expanding bio-pharmaceutical company with global operations and sales. The company would like to thank Mr. Setu Purohit for his service and his contributions and wishes him all the best in his future endeavours.
“I would like to express my gratitude to Setu for his dedication to our shared vision and contributions to bringing Avicanna from a concept to a multi-national company over the past 5 years,” said Aras Azadian, Chief Executive Officer, “His belief in cannabinoid-based medicine and his ability to help navigate the stigmatized and emerging cannabis industry from a global perspective has helped form the company’s platform.”
The Company is actively engaged in discussions with a suitable candidate for the position of Chief Legal Officer and expects to provide an update shortly.
About Avicanna Inc.
Avicanna is a commercial stage Canadian biopharmaceutical company and an established leader in cannabinoid research, development, and evidence-based products for the global consumer, medical, and pharmaceutical market segments. Avicanna conducts its research in Canada including its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada, located in the MaRS Discovery District, and in collaboration with leading Canadian academic and medical institutions.
